Microcap acne medicine maker Paratek Pharmaceuticals (PRTK - Get Report) saw shares soar Monday ahead of opening bell thanks to positive research results. The company, along with its partner, Allergan (AGN - Get Report) , said two phase three trials of its sarecycline, which could be used to treat moderate to severe acne, met their primary endpoints.

Shares of Paratek were up 15% ahead of market's open Monday, hitting $18.25 apiece. Meanwhile, Allergan's shares were down less than half a percent, hitting $236.16 before market's open.

Meanwhile, another acne drug maker Foamix Pharmaceuticals (FOMX - Get Report) struggled ahead of market's open Monday. The company lost more than half its share value ahead of the opening bell Monday.

Shares were down 50%, hitting $4.48 apiece on news that the company reported "topline" results. There is, however, some concern about consumer responses to foam based skincare products.

Impax Laboratories (IPXL) shares were soaring nearly 10% ahead of market's open on news that the company has hired a new CEO. The maker of EpiPen competitor, generic Adrenaclick, is reportedly exploring strategic alternatives, including a sale, though management would not confirm the rumors.

Shares were up $1.00 ahead of market's open, hitting $10.25 apiece.